Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

23Andme Holding Co

Healthcare US ME

NoneUSD
0.00(0%)

Last update at 2025-04-28T13:48:42.793801Z

Day Range

--
LowHigh

52 Week Range

0.352.12
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap251.48M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-298.12899M
  • Revenue TTM219.64M
  • Revenue Per Share TTM0.46
  • Gross Profit TTM 132.94M
  • Diluted EPS TTM-1.4

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -314.42800M -220.97000M -183.61900M -250.86300M -
Minority interest - - - - -
Net income -311.65600M -217.49000M -183.36400M -289.31100M -
Selling general administrative 115.98M 97.38M 99.15M 59.39M -
Selling and marketing expenses 119.93M 100.34M 43.20M 110.52M -
Gross profit 134.50M 132.94M 117.01M 137.43M -
Reconciled depreciation 36.50M 26.15M 20.25M 23.29M -
Ebit -324.01100M -254.15300M -185.19600M -213.75500M -188.78300M
Ebitda -287.51300M -260.99400M -164.95000M -145.77400M -
Depreciation and amortization 36.50M -6.84100M 20.25M 67.98M -
Non operating income net other -0.09300M 33.18M - - -
Operating income -324.01100M -254.15300M -185.19600M -213.75500M -
Other operating expenses 623.50M 526.05M 429.12M 519.22M -
Interest expense 9.58M 0.28M 1.58M 6.24M 0.00000M
Tax provision -2.77200M -3.48000M 0.00000M 0.00000M -
Interest income 9.68M - 1.58M - -
Net interest income 9.68M 0.28M 1.58M 6.24M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.77200M -3.48000M -0.25500M 38.45M -
Total revenue 299.49M 271.89M 243.92M 305.46M -
Total operating expenses 458.51M 387.10M 302.20M 351.19M -
Cost of revenue 164.99M 138.95M 126.91M 168.03M -
Total other income expense net 9.58M 33.18M 1.58M -37.10800M -
Discontinued operations - - - - -
Net income from continuing ops -311.65600M -217.49000M -183.61900M -250.86300M -
Net income applicable to common shares -311.65600M -217.49000M -183.61900M -250.86300M -183.53300M
Preferred stock and other adjustments - - - - -
Breakdown 2024-03-31 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Type yearly yearly yearly yearly yearly
Date 2024-03-31 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Total assets 395.17M 942.60M 1152.07M 452.10M -
Intangible assets - 61.18M 83.54M 6.89M -
Earning assets - - - - -
Other current assets 16.84M 19.22M 34.44M 22.37M 13.48M
Total liab 206.65M 228.66M 236.41M 1047.72M -
Total stockholder equity 188.52M 713.94M 915.66M -595.61900M -
Deferred long term liab - - - - -
Other current liab 42.26M 66.43M 44.59M 31.95M 84.75M
Common stock 0.05M 0.05M 0.04M 0.01M -
Capital stock - 0.05M 0.04M 0.01M -
Retained earnings -2173.08800M -1506.38400M -1194.72800M -977.23800M -793.61900M
Other liab - - 4.65M 1.17M 48.27M
Good will - 351.74M 351.74M 0.00000M -
Other assets 0.00000M 10.85M 10.42M 8.48M 9.05M
Cash 217.89M 386.85M 553.18M 282.49M -
Cash and equivalents - - - - -
Total current liabilities 127.33M 149.42M 153.24M 121.62M 139.45M
Current deferred revenue 64.83M 62.52M 62.94M 71.25M -
Net debt -141.37200M -301.54500M -466.87400M -188.76700M -
Short term debt 8.67M 7.54M 7.78M 6.14M -
Short long term debt - - - - -
Short long term debt total 76.52M 85.30M 86.31M 93.72M -
Other stockholder equity 2361.56M 2220.90M 2110.16M 381.62M -
Property plant equipment - 38.61M 49.85M 123.15M 137.64M
Total current assets 250.52M 424.99M 601.79M 313.57M 252.52M
Long term investments - - - - -
Net tangible assets - 301.01M 480.37M -602.50800M -626.30000M
Short term investments - - - 508.65M -
Net receivables 3.32M 1.90M 3.38M 2.48M 6.39M
Long term debt - - - - -
Inventory 12.46M 10.25M 10.79M 6.24M 14.12M
Accounts payable 11.57M 12.92M 37.93M 12.27M 13.09M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -0.62000M 0.18M -50.32800M -
Additional paid in capital - - - - -
Common stock total equity - 0.05M 0.04M 487.05M -
Preferred stock total equity - - - - -
Retained earnings total equity - -1506.38400M -1194.72800M -48.60323M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 60.43M 9.99M 9.57M 7.63M -
Deferred long term asset charges - - - - -
Non current assets total 144.65M 517.61M 550.28M 138.52M -
Capital lease obligations - 85.30M 86.31M 93.72M -
Long term debt total - - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -11.30500M -108.13700M -6.53600M -72.82300M -
Change to liabilities -25.48500M 18.74M -16.07300M -65.14200M 20.79M
Total cashflows from investing activities -11.30500M -108.13700M -6.53600M -72.82300M -27.84000M
Net borrowings - - - - -
Total cash from financing activities 9.78M 546.00M 155.34M 8.83M 344.45M
Change to operating activities - -9.41100M 5.79M 25.13M 8.60M
Net income -311.65600M -217.49000M -183.61900M -250.86300M -183.53300M
Change in cash -166.53300M 270.89M 74.55M -249.75900M 218.49M
Begin period cash flow 561.75M 290.86M 216.31M 466.07M -
End period cash flow 395.22M 561.75M 290.86M 216.31M 466.07M
Total cash from operating activities -165.39000M -166.82800M -74.25200M -185.76600M -98.11700M
Issuance of capital stock 0.00000M 309.72M 82.50M 0.00000M -
Depreciation 36.50M 26.15M 20.25M 23.29M 9.90M
Other cashflows from investing activities -7.25700M -104.16900M - - -
Dividends paid - - - - -
Change to inventory 0.54M -4.26200M 7.88M -0.44000M 12.52M
Change to account receivables 1.48M -0.89900M 3.91M 4.21M -3.88900M
Sale purchase of stock 6.46M 576.65M - - -
Other cashflows from financing activities 3.31M 236.28M 155.34M -72.82300M -0.39400M
Change to netincome 126.22M 25.03M 88.11M 78.80M 37.49M
Capital expenditures 11.30M 13.97M 7.37M 73.59M 27.40M
Change receivables 1.48M -0.89900M - - -
Cash flows other operating 11.44M -11.64300M - - -
Exchange rate changes - -0.14600M - - -
Cash and cash equivalents changes -166.91800M 270.89M - - -
Change in working capital -16.45200M -0.51500M 1.51M -36.24900M -
Stock based compensation 116.02M 57.93M 88.42M 44.84M -
Other non cash items 10.20M -32.90400M -0.87600M 33.22M -
Free cash flow -176.69500M -180.80100M -81.62600M -259.35400M -

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ME
23Andme Holding Co		 - -% - - - 0.86 0.57 0.20 -0.1682
TMO
Thermo Fisher Scientific Inc		 -8.13 1.69% 473.95 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 1.97 1.12% 178.08 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 2.35 1.74% 137.40 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 9.91 1.80% 560.73 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

23Andme Holding Co

349 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Ms. Anne Wojcicki Co-Founder, CEO, Pres & Director NA
Ms. Kathy L. Hibbs Esq., J.D. Chief Admin. Officer and Sec. 1964
Dr. Kenneth J. Hillan Ch.B., M.B. Chief Therapeutics Officer 1961
Mr. Joseph Selsavage Interim CFO & Accounting Officer 1963
Dr. Joseph R. Arron M.D., Ph.D. Chief Scientific Officer NA
Dr. Wade Walke VP of Investor Relations 1966
Ms. Jacquie Cooke Haggarty J.D. Gen. Counsel & Privacy Officer NA
Ms. Katie Watson VP of Communications 1978
Mr. Jonathan Ward Chief Marketing Officer NA
Ms. Savita Pillai VP of People NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.